Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy – a review

被引:0
作者
Julien Freitag
Dan Bates
Richard Boyd
Kiran Shah
Adele Barnard
Leesa Huguenin
Abi Tenen
机构
[1] Melbourne Stem Cell Centre,
[2] Monash University,undefined
[3] Magellan Stem Cells,undefined
[4] Metrospinal Clinic,undefined
来源
BMC Musculoskeletal Disorders | / 17卷
关键词
Mesenchymal Stem Cells; Osteoarthritis; Knee;
D O I
暂无
中图分类号
学科分类号
摘要
Osteoarthritis is a leading cause of pain and disability across the world. With an aging population its prevalence is likely to further increase. Current accepted medical treatment strategies are aimed at symptom control rather than disease modification. Surgical options including joint replacement are not without possible significant complications. A growing interest in the area of regenerative medicine, led by an improved understanding of the role of mesenchymal stem cells in tissue homeostasis and repair, has seen recent focused efforts to explore the potential of stem cell therapies in the active management of symptomatic osteoarthritis. Encouragingly, results of pre-clinical and clinical trials have provided initial evidence of efficacy and indicated safety in the therapeutic use of mesenchymal stem cell therapies for the treatment of knee osteoarthritis. This paper explores the pathogenesis of osteoarthritis and how mesenchymal stem cells may play a role in future management strategies of this disabling condition.
引用
收藏
相关论文
共 362 条
[1]  
Bitton R(2009)The economic burden of osteoarthritis Am J Manag Care 15 230-235
[2]  
Fransen M(2011)The epidemiology of osteoarthritis in Asia Int J Rheum Dis 14 113-121
[3]  
Bridgett L(2002)Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications Curr Opin Rheumatol 14 573-577
[4]  
March L(2001)Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care Ann Rheum Dis 60 91-97
[5]  
Brooks PM(2005)The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition Rheumatology 44 1531-1537
[6]  
Peat G(2006)Epidemiology of osteoarthritis: an update Curr Rheum Rep 8 7-15
[7]  
McCarney R(2012)Metabolic syndrome meets osteoarthritis Nat Rev Rheumatol 8 729-737
[8]  
Gupta S(2006)Long-term effects of intra-articular hyaluronan on synovial fluid in osteoarthritis of the knee J Rheumatol 33 946-950
[9]  
Hawker GA(2007)Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident Aliment Pharmacol Ther 25 913-924
[10]  
Issa S(2009)Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis Osteoarthritis Cartilage 17 152-160